Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565403 | 1.00 | KDM4E (0.41) | KDM4EPOLBMEN1KMT2ANPC1 | |
| SCHEMBL4565013 | 0.98 | KDM4E (0.43) | KDM4EPOLBMEN1KMT2ANPC1 | |
| SCHEMBL4565014 | 0.98 | KDM4E (0.43) | KDM4EPOLBMEN1KMT2ANPC1 | |
| SCHEMBL4543219 | 0.97 | KDM4E (0.45) | KDM4EPOLBMEN1KMT2ANPC1 | |
| SCHEMBL4543222 | 0.97 | KDM4E (0.45) | KDM4EPOLBMEN1KMT2ANPC1 | |
| SCHEMBL4565209 | 0.88 | L3MBTL1 (0.47) | KDM4EPOLBMEN1KMT2ATSHR | |
| SCHEMBL4564946 | 0.88 | L3MBTL1 (0.47) | KDM4EPOLBMEN1KMT2ATSHR | |
| SCHEMBL6730780 | 0.87 | PIK3CB (0.45) | MEN1KMT2ATSHRPTPN1HRH1 | |
| SCHEMBL29824477 | 0.87 | PIK3CB (0.45) | MEN1KMT2ATSHRPTPN1HRH1 | |
| SCHEMBL24632233 | 0.87 | DRD4 (0.33) | KDM4EPOLBMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902727-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9902727-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-20150080374-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080374-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-8895549-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895549-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| EP-2638045-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062748-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062748-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080374-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3C2A | KDM4E 3826/4885POLB 790/4885MEN1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.